CVRx (CVRX) Set to Announce Earnings on Tuesday

CVRx (NASDAQ:CVRX) is scheduled to announce its earnings results after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings data on Thursday, January 25th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.11. The firm had revenue of $11.31 million during the quarter, compared to analysts’ expectations of $10.90 million. CVRx had a negative return on equity of 47.30% and a negative net margin of 104.85%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Performance

NASDAQ:CVRX opened at $14.69 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 12.86 and a current ratio of 14.25. CVRx has a fifty-two week low of $9.18 and a fifty-two week high of $33.13. The company has a market cap of $317.23 million, a price-to-earnings ratio of -7.42 and a beta of 1.29. The stock has a fifty day moving average price of $19.58 and a 200-day moving average price of $21.02.

Insider Buying and Selling at CVRx

In other CVRx news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Paul Verrastro sold 2,545 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $21.91, for a total value of $55,760.95. Following the completion of the transaction, the insider now directly owns 2,455 shares in the company, valued at approximately $53,789.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 18.30% of the company’s stock.

Wall Street Analysts Forecast Growth

CVRX has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of CVRx from $31.00 to $36.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Piper Sandler upped their price target on shares of CVRx from $21.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, January 26th. Finally, Lake Street Capital lifted their price objective on shares of CVRx from $21.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, December 27th.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.